|
US5178878A
(en)
|
1989-10-02 |
1993-01-12 |
Cima Labs, Inc. |
Effervescent dosage form with microparticles
|
|
US5558880A
(en)
|
1989-12-22 |
1996-09-24 |
Janssen Pharmaceutica Inc. |
Pharmaceutical and other dosage forms
|
|
US5464632C1
(en)
|
1991-07-22 |
2001-02-20 |
Prographarm Lab |
Rapidly disintegratable multiparticular tablet
|
|
GB9504201D0
(en)
|
1995-03-02 |
1995-04-19 |
Scherer Ltd R P |
Process for the preparation of a solid pharmaceutical dosage form
|
|
TW486370B
(en)
|
1996-12-25 |
2002-05-11 |
Yamanouchi Pharma Co Ltd |
Rapidly disintegrable pharmaceutical composition
|
|
US6024981A
(en)
|
1997-04-16 |
2000-02-15 |
Cima Labs Inc. |
Rapidly dissolving robust dosage form
|
|
US6433154B1
(en)
|
1997-06-12 |
2002-08-13 |
Bristol-Myers Squibb Company |
Functional receptor/kinase chimera in yeast cells
|
|
FR2766089B1
(fr)
|
1997-07-21 |
2000-06-02 |
Prographarm Lab |
Comprime multiparticulaire perfectionne a delitement rapide
|
|
KR100554924B1
(ko)
|
1998-05-18 |
2006-03-03 |
다케다 야쿠힌 고교 가부시키가이샤 |
구강내 붕괴 정제
|
|
US6350786B1
(en)
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
EP1027886B1
(en)
|
1999-02-10 |
2008-07-09 |
Pfizer Products Inc. |
Pharmaceutical solid dispersions
|
|
US6764720B2
(en)
|
2000-05-16 |
2004-07-20 |
Regents Of The University Of Minnesota |
High mass throughput particle generation using multiple nozzle spraying
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
JP2005500313A
(ja)
|
2001-06-22 |
2005-01-06 |
ファイザー・プロダクツ・インク |
基材中の低可溶性薬物の固体分散体および溶解度向上性ポリマーを含有する医薬品組成物
|
|
CN1688291A
(zh)
|
2002-02-01 |
2005-10-26 |
辉瑞产品公司 |
含有固体药物分散体的即刻释放剂型
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
EP1670441A4
(en)
|
2003-10-07 |
2012-05-02 |
Andrx Pharmaceuticals Llc |
FAST RESOLUTION FORMULATION
|
|
MXPA06013891A
(es)
|
2004-05-28 |
2007-01-26 |
Pfizer Prod Inc |
Composiciones farmaceuticas con comportamiento potenciado.
|
|
DE102005009240A1
(de)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
|
|
GT200600316A
(es)
|
2005-07-20 |
2007-04-02 |
|
Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
|
|
GT200600315A
(es)
|
2005-07-20 |
2007-03-19 |
|
Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
|
|
EP2529761B1
(en)
|
2006-01-31 |
2017-06-14 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
|
US7951428B2
(en)
|
2006-01-31 |
2011-05-31 |
Regents Of The University Of Minnesota |
Electrospray coating of objects
|
|
US9108217B2
(en)
|
2006-01-31 |
2015-08-18 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
|
EP1923053A1
(en)
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
MX2009004861A
(es)
|
2006-11-09 |
2009-05-21 |
Abbott Gmbh & Co Kg |
Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
|
|
EP1920767A1
(en)
|
2006-11-09 |
2008-05-14 |
Abbott GmbH & Co. KG |
Melt-processed imatinib dosage form
|
|
US9040816B2
(en)
|
2006-12-08 |
2015-05-26 |
Nanocopoeia, Inc. |
Methods and apparatus for forming photovoltaic cells using electrospray
|
|
EP2162120B1
(en)
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
|
TWI547282B
(zh)
|
2007-07-02 |
2016-09-01 |
愛戴爾製藥股份有限公司 |
樂命達之口服分解錠劑組合物
|
|
WO2009010837A2
(en)
|
2007-07-13 |
2009-01-22 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
|
|
US8992471B2
(en)
|
2007-11-05 |
2015-03-31 |
Nanocopoeia, Inc. |
Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity
|
|
US20090203709A1
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
|
|
CA2717947C
(en)
|
2008-03-11 |
2020-07-07 |
Takeda Pharmaceutical Company Limited |
Orally-disintegrating solid preparation
|
|
GB0816365D0
(en)
*
|
2008-09-08 |
2008-10-15 |
Univ Belfast |
Polymeric material
|
|
CZ20098A3
(cs)
|
2009-01-13 |
2010-07-21 |
Zentiva, K.S. |
Lékové formy inhibitoru tyrosinových kináz
|
|
US8545879B2
(en)
|
2009-08-31 |
2013-10-01 |
Wilmington Pharmaceuticals, Llc |
Fast disintegrating compositions of meloxicam
|
|
FI4066821T3
(fi)
|
2009-11-09 |
2025-05-13 |
Wyeth Llc |
Neratinibimaleaatin tablettiformulaatioita
|
|
JO3634B1
(ar)
|
2009-11-17 |
2020-08-27 |
Novartis Ag |
طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
|
|
KR20130109092A
(ko)
|
2010-06-09 |
2013-10-07 |
아보트 러보러터리즈 |
키나제 억제제를 함유하는 고체 분산물
|
|
US9757456B2
(en)
|
2010-09-14 |
2017-09-12 |
Nanologica Ab |
Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients and suppression of crystallization of pharmaceutical active ingredients
|
|
US10562048B2
(en)
|
2011-01-19 |
2020-02-18 |
Nanocopoeia, Llc |
Electrohydrodynamic atomization nozzle emitting a liquid sheet
|
|
WO2012164578A1
(en)
|
2011-06-02 |
2012-12-06 |
Hetero Research Foundation |
Compositions and methods for preparing immediate release formulations of nilotinib
|
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
|
US20130096116A1
(en)
|
2011-10-13 |
2013-04-18 |
Genentech, Inc. |
Treatment of pharmacological-induced hypochlorhydria
|
|
US9301957B2
(en)
|
2011-11-14 |
2016-04-05 |
Novartis Ag |
Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
|
|
DK2802314T3
(da)
|
2012-01-13 |
2021-01-25 |
Xspray Microparticles Ab |
Fremgangsmåde til fremstilling af stabile, amorfe hybride nanopartikler, der omfatter mindst én proteinkinaseinhibitor og mindst én polymer stabiliserende og matrixdannende bestanddel
|
|
DK3181122T3
(da)
|
2012-01-13 |
2023-06-06 |
Xspray Pharma Ab Publ |
Farmaceutisk dasatinib-sammensætning
|
|
US20130274342A1
(en)
|
2012-04-12 |
2013-10-17 |
Cerecor, Inc. |
Compositions and methods for treating cough
|
|
US10195150B2
(en)
|
2012-12-20 |
2019-02-05 |
Kashiv Pharma, Llc |
Orally disintegrating tablet formulation for enhanced bioavailability
|
|
TW201446286A
(zh)
|
2013-01-31 |
2014-12-16 |
Gilead Pharmasset Llc |
抗病毒化合物之固態分散調製劑
|
|
US20160346198A1
(en)
|
2014-02-05 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Novel disintegration systems for pharmaceutical dosage forms
|
|
WO2015120110A2
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
HU231013B1
(hu)
|
2014-05-26 |
2019-11-28 |
Egis Gyógyszergyár Zrt. |
Dasatinib sók
|
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
US20160235677A1
(en)
|
2014-11-25 |
2016-08-18 |
Nanocopoeia, Llc. |
Method of converting a crystalline compound to an amorphous compound, method of increasing the solubility of a crystalline compound in a biorelevant fluid, and nanoparticles that achieve supersaturation
|
|
WO2016097011A1
(en)
|
2014-12-19 |
2016-06-23 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous nilotinib
|
|
US20160175881A1
(en)
|
2014-12-22 |
2016-06-23 |
Nanocopoeia, Llc |
Electrospray methods, electrospray systems, and methods of forming crystalline particles
|
|
KR102431738B1
(ko)
|
2014-12-25 |
2022-08-10 |
주식회사 다이셀 |
초고속 붕해 정제 및 그 제조 방법
|
|
US9925138B2
(en)
|
2015-01-20 |
2018-03-27 |
Handa Pharmaceuticals, Llc |
Stable solid fingolimod dosage forms
|
|
PT108368B
(pt)
|
2015-03-31 |
2018-11-05 |
Hovione Farm S A |
Produção contínua de partículas
|
|
US10265301B2
(en)
|
2015-06-17 |
2019-04-23 |
Dispersol Technologies, Llc |
Formulations of deferasirox and methods of making the same
|
|
JP6507272B2
(ja)
|
2015-07-27 |
2019-04-24 |
ユニケム ラボラトリーズ リミテッド |
トファシチニブ口腔内崩壊錠
|
|
WO2017064538A1
(en)
|
2015-10-16 |
2017-04-20 |
Nobel Ilac Sanayii Ve Ticaret A.S. |
Pharmaceutical compositions of nilotinib hydrochloride
|
|
WO2017108605A1
(en)
|
2015-12-22 |
2017-06-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous dasatinib
|
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
|
WO2018078392A1
(en)
|
2016-10-29 |
2018-05-03 |
Cipla Limited |
Polymorphs of dasatinib
|
|
KR102333609B1
(ko)
|
2017-10-31 |
2021-12-01 |
주식회사 삼양홀딩스 |
붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
|
|
WO2019151405A1
(ja)
|
2018-02-02 |
2019-08-08 |
ニプロ株式会社 |
錠剤及びその製造方法
|
|
CN120305263A
(zh)
|
2018-06-15 |
2025-07-15 |
汉达癌症医药责任有限公司 |
卡博替尼的盐类于制备治疗癌症的剂型的用途
|
|
CN113573712A
(zh)
*
|
2019-02-18 |
2021-10-29 |
斯莱班克制药有限责任公司 |
尼洛替尼的药物组合物
|
|
EP4096791A1
(en)
|
2020-01-31 |
2022-12-07 |
Nanocopoeia LLC |
Amorphous nilotinib microparticles and uses thereof
|
|
EP4101015A4
(en)
*
|
2020-02-06 |
2024-10-30 |
Briggs & Stratton (Shanghai) International Trading Co., Ltd. |
BATTERY PACK FOR BATTERY-OPERATED DEVICE
|
|
IL297776A
(en)
|
2020-04-30 |
2022-12-01 |
Nanocopoeia Llc |
Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
|
|
US20220378788A1
(en)
|
2020-04-30 |
2022-12-01 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
|